The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 28, 2019
Filed:
May. 01, 2017
Applicant:
Immunogen, Inc., Waltham, MA (US);
Inventors:
Olga Ab, Millis, MA (US);
Daniel Tavares, Natick, MA (US);
Lingyun Rui, Weston, MA (US);
Gillian Payne, Waban, MA (US);
Viktor S. Goldmakher, Newton, MA (US);
Assignee:
ImmunoGen, Inc., Waltham, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/395 (2006.01); A61K 51/10 (2006.01); C12N 15/79 (2006.01); A61K 45/06 (2006.01); A61K 31/5365 (2006.01); A61K 47/68 (2017.01); A61K 47/54 (2017.01); A61K 31/537 (2006.01); C12N 15/63 (2006.01); C12N 5/16 (2006.01); C07H 21/00 (2006.01); C12N 15/62 (2006.01); C12N 15/70 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 31/537 (2013.01); A61K 31/5365 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/545 (2017.08); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6889 (2017.08); C07K 16/30 (2013.01); C07K 16/3069 (2013.01); A61K 2039/505 (2013.01); C07H 21/00 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/624 (2013.01); C07K 2317/626 (2013.01); C07K 2317/71 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C12N 5/16 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); C12N 15/70 (2013.01); C12N 15/79 (2013.01); C12N 2800/00 (2013.01);
Abstract
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.